Medindia

X

For the Treatment of Chronic Tophaceous Gout, a Drug That Resolves Tophi in Less Than One Year Would Become the Patient Share Leader in the U.S. and Europe

Monday, January 11, 2010 Drug News J E 4
Advertisement
Savient Pharmaceuticals' Krystexxa Will Become Decision Resources' Clinical Gold Standard in 2013

Gisselle Morales

Elizabeth Marshall

Decision Resources

Decision Resources, Inc.

781-296-2691

781-296-2563

gmorales@dresources.com

emarshall@dresources.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Caliper Licenses Microfluidics IP to Becton Dickin...
S
Echo Therapeutics Announces Major Milestone: The C...